# Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

> **NCT03719313** · PHASE3 · COMPLETED · sponsor: **Eiger BioPharmaceuticals** · enrollment: 407 (actual)

## Conditions studied

- Hepatitis Delta Virus

## Interventions

- **DRUG:** Lonafarnib
- **DRUG:** Ritonavir
- **DRUG:** PEG IFN-alfa-2a
- **DRUG:** Placebo Lonafarnib
- **DRUG:** Placebo Ritonavir

## Key facts

- **NCT ID:** NCT03719313
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2022-10-06
- **Final completion:** 2023-03-24
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719313, "Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03719313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*